EBR Systems Inc (ebr) Logo

EBR Systems Inc (EBR)

___:___ · Healthcare

EBR Chart


EBR's Principal Activity is the medical device company focussed on developing and bringing to market, devices to treat patients with certain types of heart failure.

Share Price Activity

Last (Price)
Change 0.00 (0.00)
Bid / Ask -
Volume (4w avg)
Day Range -
Prev Close
Last Trade


1 Week
1 Month
2022 YTD
1 Year
vs Sector (1yr) -
vs ASX 200 (1yr) -60.59%


Market Cap Question Mark Icon
Excludes mandatory escrowed shares and foreign shares.
ASX Rank 964 of 2,413
Sector Rank 69 of 210

Key Fundamentals

Shares Issued
Sector Healthcare
Similar Companies CAN / AVH / AHX
EPS $0.00
DPS $0.00
Book Value Per Share $0.00

Broker Consensus

EBR is not covered by a major broker, or data from most recent compilation was omitted due to not meeting QA guidelines.


Date Heading Pages File Size Time

Corporate Overview

EBR Systems Inc (EBR) is a United States based company dedicated to treatment of cardiac rhythm disease by providing physiologically effective stimulation through cardiac pacing. The Company's patented Wireless Stimulation Endocardially (WiSE) technology was developed to eliminate the need for cardiac pacing leads, historically the source of complications and reliability issues in cardiac rhythm management.

Incorporation Details

No incorporation details available.

Corporate Details

Head Office Sunnyvale CA USA 94085
Website www.ebrsystemsinc.com
Registry Computershare
Auditor Grant Thornton Corporate Finance Pty Limited
Date Listed 24 Nov 2021

Upcoming Calendar (Forecasted)

Date Event
24/02/2023 Report (Prelim)
27/04/2023 Report (Annual)

Dividend History

DPS and Yield calculations use the Pay Date.

Ex-Date Amount Franking Gross Type Payable
No dividends paid.

See Upcoming Dividends for all ASX companies.

Directors & Management

Directors & Management

Name Title Since Bio
Ms Karen Ruth Drexler Non-Executive Director Oct 2021

Ms Karen Ruth Drexler

Non-Executive Director

Ms Drexler is a serial entrepreneur with expertise in the fields of digital health, medical devices, and diagnostics. Ms Drexler serves on the boards of two other public companies, Resmed, Inc. (NYSE, ASX:RMD), where she serves on the compensation and nominating and governance committees, and Outset Medical Inc.(NASDAQ: OM), where she chairs the compensation committee and serves on the nominating and governance committee. Ms Drexler is also on the board of three private companies: Bone Health Technologies Inc., VIDA Diagnostics Inc. and Tivic Health Systems, Inc.. Ms Drexler also acts as a senior strategic advisor for other early-stage companies, and spent 11 years on the board of the Keller Center for Innovation in Engineering Education at Princeton University. Ms Drexler is an active mentor and advisor with Astia. She is a founding member of Astia Angels and a lead mentor with StartX, the Stanford University incubator. She is also on the Life Science and Women's Health Councils for Springboard.

Dr Bronwyn Joy Evans Non-Executive Director Oct 2021

Dr Bronwyn Joy Evans

Non-Executive Director

Dr Evans is an experienced leader and CEO with a technical background across multiple industry sectors including medical technology, manufacturing, power generation and distribution and technical regulation and standards. Dr Evans is currently the CEO of Engineers Australia, the Chair of Building4.0 CRC, and the Director at GME Pty Ltd. Prior to her role with Engineers Australia, Dr Evans was the CEO of Standards Australia. Dr Evans has previously held positions in innovation initiatives, including as Chair of MTPConnect and was a member of the Industry 4.0 Advanced Manufacturing Forum Leadership group. She has also held various senior engineering roles, including at Cochlear and GE Healthcare. She is an Honorary Fellow of the University of Wollongong and Engineers Australia and a Fellow of the Australian Academy of Technological Sciences and Engineering. She also chairs Risk Committee.

Dr David Mark Steinhaus Non-Executive Director Oct 2021

Dr David Mark Steinhaus

Non-Executive Director

Dr Steinhaus retired in 2019 as Vice President and General Manager of the Heart Failure Business for the Cardiac Rhythm and Heart Failure Division at Medtronic plc (NYSE:MDT). Dr Steinhaus joined Medtronic in 2005, after 20 years of cardiology (electrophysiology) practice. His responsibilities at Medtronic included bringing the physician voice to CRHF, identifying future opportunities in new product development, and serving as a liaison to government agencies, professional societies and medical groups. Dr Steinhaus has been closely associated with research and academia, performing clinical studies in implantable cardiac devices and leads. He served as Chair of the Department of Cardiology, and Director of the Electrophysiology Department at the Mid America Heart Institute and St. Luke's Hospital and Director of the Electrophysiology Fellowship Program at the University of Missouri at Kansas City School of Medicine, and has instructed students in medicine since 1982. Since leaving Medtronic, he has served as a consultant and board member to multiple established and early stage medical device companies. He is currently the Executive Chairman of the board of Enopace Biomedical Ltd., a company which produces therapeutic neuromodulation devices for the treatment of heart failure. He is also a member of Risk Committee.

Mr John Graham McCutcheon Chief Executive Officer,President,Executive Director Jun 2019

Mr John Graham McCutcheon

Chief Executive Officer,President,Executive Director

Mr McCutcheon has served as President and CEO of EBR since June 2019 and is responsible for the overall management and strategic direction of EBR. Mr McCutcheon has over 35 years of experience in sales, marketing, and management of medical device companies. Prior to joining EBR, Mr McCutcheon was the President and CEO of Ceterix Orthopaedics, Inc. for nine years from 2010 to 2019. He also held CEO roles at Ventus Medical, Inc. (2009-2010) and Emphasys Medical, Inc. (2000-2009).

Dr Christopher Dean Nave Non-Executive Director Oct 2017

Dr Christopher Dean Nave

Non-Executive Director

Dr Nave is a founder and Managing Director of Brandon Capital Partners and the CEO of the Medical Research Commercialisation Fund. Dr Nave previously served as the Director of Commercialisation at the Baker Heart Research Institute. Dr Nave is currently a director of The Australian Investment Council, Azura Ophthalmics, Inc., Certa Therapeutics Pty Ltd, Global Kinetics Corporation Ltd, OccuRx Pty. Ltd., Osprey Medical, Inc. (ASX:OSP), PolyActiva Pty Ltd and Que Oncology, Inc. Dr Nave was also a chairperson of Fibrotech Therapeutics Pty Ltd and a director of Spinifex Pharmaceuticals, Inc. He is also a member of Risk Committee.

Mr Trevor John Moody Non-Executive Director Oct 2017

Mr Trevor John Moody

Non-Executive Director

Mr Moody currently serves as Medical Device Partner at M.H. Carnegie & Co. (since October 2013), where he makes investments in medical device companies. He has also served since January 2010 as President of TM Strategic Advisors LLC, a management consultancy. Mr Moody was previously a General Partner at Frazier Healthcare Ventures. Mr Moody is currently a director of electroCore, Inc. (NASDAQ: ECOR), Australian Medtech Services Pty Ltd, Cardiac Dimensions Pty Ltd, Renew Medical Pty Ltd, Serene Medical Pty Limited, The Brain Protection Company Pty Ltd, and CurvaFix, Inc. Mr Moody also serves on the board of Angel Flight West, a not-for-profit that provides free air transport for patients requiring long distance travel for medical treatment. Mr Moody was a director of Simplify Medical Pty Ltd at the time of its sale to NuVasive, Inc. (NASDAQ: NUVA).

Mr Allan Roger Will Executive Chairman,Executive Director May 2003

Mr Allan Roger Will

Executive Chairman,Executive Director

Mr Will is a seasoned executive with experience founding, funding, operating, and selling medical device companies. In addition to his role with the Company, Mr Will currently serves as chair of the boards of Fractyl Health, Inc. and SetPoint Medical Corporation, and a director of Fogarty Innovation, a not-for-profit institute promoting innovation in medical technology founded by Dr Thomas J Fogarty. Mr Will was also founding Managing Director of Split Rock Partners' Silicon Valley office, focusing on therapeutic medical devices, having joined Split Rock Partners' predecessor entity St. Paul Venture Capital (SPVC) in 2002. Mr Will was founder, chair and CEO of The Foundry, co-founding 11 companies there, including Ardian, Evalve, Inc. and Concentric Medical Inc. Mr Will is an inventor on more than 30 issued patents, is a University of Maryland Distinguished Alumnus and a recipient of the ASTIA/Deloitte Excellence in Mentoring Women Executives Award. He served on the MIT Entrepreneurship Center Shareholders' Board and the University of Maryland President's Committee on Innovation and Entrepreneurship.

Mr Brendan Case Company Secretary N/A

Director Interests

The current holdings of EBR directors.

Director Last Notice Direct Shares Indirect Shares Options Convertibles
David Steinhaus 01/10/2021 N/A N/A 100,100 N/A
Bronwyn Evans 01/10/2021 N/A 50,037 100,100 N/A
Karen Drexler 01/10/2021 N/A N/A 100,100 N/A
John McCutcheon 17/06/2019 N/A N/A 8,511,057 N/A
Trevor Moody 30/10/2017 N/A N/A 100,100 N/A
Christopher Nave 30/10/2017 N/A N/A 100,100 N/A
Allan Will 09/05/2003 5,827,224 600,000 2,535,185 N/A

Shareholder Info

Top 20 Shareholders

Data supplied by Morningstar and accurate on Nov 19, 2021.

It's not possible to publish a real-time Top 20 Shareholder list. Companies are not obliged to report this data (with the exception of Substantial Shareholders above 5%). If a company chooses to publish the data, it's usually once a year in their Annual Report.

All data is manually compiled so there might be a delay between the Annual Report being published and the data appearing on Market Index (<7 days for ASX 300 and up to 30 days for micro-caps).

Name Shares Capital
CHV III LP 12,818,782 4.78%

Shareholder Distribution

As reported in the most recent Annual Report.

Holding Size 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001+ Total
No. of Shareholders 18 476 535 957 97 2,083

Substantial Shareholders

No Substantial Shareholders for EBR in our database.

Shareholders Buying

12 month transaction history compiled from ASX announcements.

No buy transactions reported by Substantial Shareholders in the past 12 months.

Shareholders Selling

12 month transaction history compiled from ASX announcements.

No sell transactions reported by Substantial Shareholders in the past 12 months.

Historical Data

Share Price History

Date Close Change %Chg Open High Low Volume Turnover

Historical Data

Year Closing Price Last Trade
No Financial Year End data available
EBR Historical Price Data (CSV)
Up to 20 years of EOD share price history
You must be logged in to access this feature. Please sign up for free or login.
Market Index, ASX and Morningstar Logos

All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.